Assessing in vivo presentation of exogenous antigen in the tumor microenvironment in mice

Briana G Nixon; Liangliang Ji; Ming O Li

doi:10.1016/j.xpro.2023.102185

Assessing in vivo presentation of exogenous antigen in the tumor microenvironment in mice

STAR Protoc. 2023 Mar 22;4(2):102185. doi: 10.1016/j.xpro.2023.102185. Online ahead of print.

Authors

Briana G Nixon¹, Liangliang Ji², Ming O Li³

Affiliations

¹ Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School of Biomedical Sciences, Cornell University, New York, NY 10065, USA. Electronic address: nixonb@mskcc.org.
² Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
³ Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Immunology and Microbial Pathogenesis Graduate Program, Weill Cornell Graduate School of Biomedical Sciences, Cornell University, New York, NY 10065, USA. Electronic address: lim@mskcc.org.

Abstract

Here, we focus on tumor-associated macrophages (TAMs) in the PyMT model of breast cancer, detailing a protocol for assessing antigen presentation capabilities of immune populations of interest. We describe a stringent bone marrow chimera system to demonstrate presentation of exogenous antigen that is acquired and processed in the tumor microenvironment. We describe steps for testing antigen presentation activity of TAMs to CD8⁺ T cells in vivo and ex vivo and the requirement for the transcription factor IRF8 in this function. For complete details on the use and execution of this protocol, please refer to Nixon et al. (2022).¹.

Keywords: Cancer; Cell Biology; Cell culture; Cell isolation; Flow Cytometry/Mass Cytometry; Immunology; Model Organisms.

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States